# Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects

> **NCT02927457** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 11 (actual)

## Conditions studied

- Lupus Erythematosus, Cutaneous

## Interventions

- **DRUG:** GSK2646264 1%
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02927457
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-13
- **Primary completion:** 2018-06-12
- **Final completion:** 2018-06-12
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02927457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02927457, "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02927457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*